Empowered Funds LLC Buys 13,534 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Empowered Funds LLC lifted its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 5.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 266,838 shares of the company’s stock after acquiring an additional 13,534 shares during the period. Empowered Funds LLC owned 0.31% of Pediatrix Medical Group worth $3,093,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Rubric Capital Management LP boosted its stake in Pediatrix Medical Group by 797.0% in the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after acquiring an additional 7,241,400 shares in the last quarter. Dana Investment Advisors Inc. boosted its position in shares of Pediatrix Medical Group by 80.3% in the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after purchasing an additional 455,785 shares in the last quarter. Boston Partners boosted its position in shares of Pediatrix Medical Group by 34.0% in the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after purchasing an additional 453,254 shares in the last quarter. Cubist Systematic Strategies LLC increased its position in Pediatrix Medical Group by 639.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock valued at $2,192,000 after buying an additional 251,072 shares in the last quarter. Finally, ClariVest Asset Management LLC acquired a new position in Pediatrix Medical Group during the 2nd quarter valued at about $1,721,000. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

Pediatrix Medical Group Trading Up 2.3 %

Shares of Pediatrix Medical Group stock opened at $14.47 on Tuesday. The stock has a market cap of $1.24 billion, a PE ratio of -4.73, a price-to-earnings-growth ratio of 2.03 and a beta of 1.55. The firm has a fifty day moving average price of $12.61 and a 200 day moving average price of $9.89. Pediatrix Medical Group, Inc. has a 1 year low of $6.62 and a 1 year high of $16.41. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company’s revenue was up .9% on a year-over-year basis. During the same quarter last year, the business posted $0.29 EPS. Equities research analysts predict that Pediatrix Medical Group, Inc. will post 1.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MD has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft boosted their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. UBS Group boosted their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Truist Financial raised their price target on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a report on Wednesday, November 13th. Finally, Mizuho raised their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pediatrix Medical Group currently has an average rating of “Hold” and a consensus target price of $16.10.

Insider Transactions at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the sale, the director now directly owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Laura A. Linynsky sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the sale, the director now owns 30,805 shares of the company’s stock, valued at $343,783.80. This trade represents a 18.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 53,808 shares of company stock valued at $751,277 in the last 90 days. 2.00% of the stock is currently owned by company insiders.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.